Improving the quality of life for more people
Highlights from the 2024 Annual Report: Sustainability.
Cinclus Pharma’s vision is to improve the quality of life for people around the world living with gastric acid-related diseases and other diseases of the upper gastrointestinal tract. If the company’s innovative drug candidate is approved and commercialized, it could help improve the quality of life for many patients living with GERD and H. pylori. On an overall level, effective treatment and faster diagnosis can also help reduce the environmental impact through reduced use of medicines and shorter periods of treatment.
The sustainability work within Cinclus Pharma will be further developed in 2025 and the company intends to establish a roadmap for the coming years.
By including patients outside the U.S. and the EU, larger value creation is possible. Cinclus Pharma aims to lay the foundation for wide patient access, helping a large number of patients in need of a more efficacious therapy through the selection of clinical trial sites in the Phase III study program and a regulatory and commercial strategy with high impact value creation prioritised.
Cinclus Pharma believes that commercial value creation, ESG and societal impact in the form of improved quality of life goes hand in hand and that the importance of these matters will further increase in significance over the years to come. The Company’s impact objectives, which is informed by this fundamental belief consists of three parts:
Improving the current standard of care
Cinclus Pharma aims to introduce new products that impact the current standard of care for gastric acid-related diseases and H. pylori infection, underpinned by linaprazan glurate. Cinclus Pharma believes that linaprazan glurate has the potential to drive a paradigm shift in this field and improve the quality of life for patients suffering from gastric acid-related diseases.
Heal/eradicate H. pylori infection and combat antimicrobial resistance
The rate of cured H. pylori infection is decreasing globally
due to increasing antibiotic resistance. H. pylori is included on WHO’s list of ’high priority pathogens’ as well as FDA’s list of ”qualifying pathogens” as a bacteria that has the potential to pose a serious threat to public health.
The current standard of care for eradication of H. pylori is a therapy with two antibiotics combined with a PPI. Linaprazan glurate holds the potential to decrease the use of antibiotics by introducing a dual therapy with only one antibiotic, thereby contributing to reducing the use of antibiotics and the development of antimicrobial resistance.
Peter Unge (Senior Advisor and Board Member of Cinclus Pharma) is the inventor of the treatment method for eradicating H. pylori. By combining acid control with antimicrobial substances and specifically dual therapy with amoxicillin in combination with an acid blocker, eradication of H. pylori is achieved.
Expanding the geographical reach
In addition to the company’s target population in the US and EU30, Cinclus Pharma intends to reach a larger patient population outside of high-income countries, through its strategy of reaching out broadly to patients. Beyond the patient and community perspective, Cinclus Pharma works to ensure that every employee has a safe, healthy and stimulating workplace. Furthermore, Cinclus Pharma stands for a non-discriminatory workplace with equal rights for all.